EUVIMEDEUVIMED entdecken
Crossref

Pharmacological Targeting of PARP‐1‐NLRP3 Inflammasome Pathway in Colitis‐Associated Colorectal Neoplasia: Effects of 3‐aminobenzamide and Olaparib

Shivani Singla iD, Rajat Pant, Vinod Kumar, Kulbhushan Tikoo, Gopabandhu Jena iD

Journal of Biochemical and Molecular Toxicology · 2026

DOI: 10.1002/jbt.70698 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2026. Verfasst von Shivani Singla und 4 weiteren Autor:innen. Beteiligte Einrichtung: Facility for Risk Assessment and Intervention Studies, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and …. Hauptthemen laut MEDLINE: Piperazines, Benzamides, NLR Family, Pyrin Domain-Containing 3 Protein, Poly (ADP-Ribose) Polymerase-1. Die Arbeit nennt 65 Literaturangaben. Gefördert von: Department of Science and Technology (DST), New Delhi, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colitis‐associated colorectal neoplasia is the third most life‐threatening consequence of prolonged ulcerative colitis. In the present investigation, we evaluated the efficacy of PARP‐1 inhibitors, 3‐aminobenzamide and Olaparib, in a rodent model of colitis‐associated colorectal cancer (CACC) induced by azoxymethane (AOM) and Dextran sulphate sodium (DSS). For model induction, male BALB/c mice were provided DSS (3% w/v) in three cycles within drinking water following an injection of AOM (10 mg/kg, intraperitoneally). A week after the DSS treatment, 3‐aminobenzamide (5, 10 and 20 mg/kg; i.p.) and Olaparib (10 mg/kg; orally) were given until sacrifice. PARP inhibitors reduced tumour progression by down‐regulating mRNA expression for inflammatory markers, PARP‐1, NLRP3, ASC, Caspase‐1, and TNF‐α. Immunoblotting showed modulation of beclin‐1 expression, while transmission electron microscopy results revealed an increase in autophagosome numbers within tumour tissues. Immunofluorescence for Ki67 and immunoblotting of PCNA indicated elevated cell proliferation in the AOM/DSS group, mitigated by the treatment with 3‐aminobenzamide (20 mg/kg) and Olaparib (10 mg/kg). Finally, DNA damage was also reduced by the intervention of 3‐aminobenzamide and Olaparib as indicated by decrease γH2AX expression. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay and β‐catenin expression suggested decrease apoptosis within tumour tissue. Both 3‐aminobenzamide (20 mg/kg; i.p.) and Olaparib (10 mg/kg; orally) exhibited coloprotective effects by modulating PARP‐1‐NLRP3 inflammasome and autophagy pathways in a model of colitis‐associated colorectal cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperazinesBenzamidesNLR Family, Pyrin Domain-Containing 3 ProteinPoly (ADP-Ribose) Polymerase-1PhthalazinesInflammasomesPoly(ADP-ribose) Polymerase InhibitorsColitis-Associated NeoplasmsColitisColorectal NeoplasmsSignal TransductionAnimalsMaleMice, Inbred BALB CMiceDextran Sulfate

Stichwörter der Autor:innen

NLRP3PARP‐1apoptosisautophagycolitis associated colorectal cancerinflammation

Substanzen

PiperazinesBenzamides3-aminobenzamideNLR Family, Pyrin Domain-Containing 3 ProteinPoly (ADP-Ribose) Polymerase-1olaparibPhthalazinesInflammasomesNlrp3 protein, mousePoly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Facility for Risk Assessment and Intervention Studies, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, S.A.S Nagar, Punjab, India.
  • Laboratory of Epigenetics and Diseases, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, S.A.S Nagar, Punjab, India.
  • High resolution Transmission Electron Microscopy Facility, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, S.A.S Nagar, Mohali, Punjab, India.

ORCID-Profile: Shivani Singla, Gopabandhu Jena

Förderung

  • Department of Science and Technology (DST), New Delhi
  • National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar

Zitieren

APA

Singla, S., Pant, R., Kumar, V., Tikoo, K., & Jena, G. (2026). Pharmacological Targeting of PARP‐1‐NLRP3 Inflammasome Pathway in Colitis‐Associated Colorectal Neoplasia: Effects of 3‐aminobenzamide and Olaparib. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.70698

Vancouver

Singla S, Pant R, Kumar V, Tikoo K, Jena G. Pharmacological Targeting of PARP‐1‐NLRP3 Inflammasome Pathway in Colitis‐Associated Colorectal Neoplasia: Effects of 3‐aminobenzamide and Olaparib. Journal of Biochemical and Molecular Toxicology. 2026. doi:10.1002/jbt.70698

BibTeX
@article{Singla2026,
  author = {Singla, Shivani and Pant, Rajat and Kumar, Vinod and Tikoo, Kulbhushan and Jena, Gopabandhu},
  title = {Pharmacological Targeting of PARP‐1‐NLRP3 Inflammasome Pathway in Colitis‐Associated Colorectal Neoplasia: Effects of 3‐aminobenzamide and Olaparib},
  journal = {Journal of Biochemical and Molecular Toxicology},
  year = {2026},
  doi = {10.1002/jbt.70698}
}
Kostenlos starten →